SCHEMBL22554028

SCHEMBL22554028

CS(=O)(=O)N1Cc2nccc(-c3cncc(-c4ccc(N5CCCC5=O)cc4)c3)c2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 1/20 0.40
GAA P10253 1/20 0.39
NPC1 O15118 2/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
AKR1C3 P42330 5/20 0.37
PKM P14618 1/20 0.36
PIP4K2A P48426 2/20 0.35
PIP4K2C Q8TBX8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PIP4K2B P78356 1/20 0.35
CYP11B2 P19099 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
CD38 P28907 1/20 0.35
TP53 P04637 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30731000 1.00 MEN1 (0.40) MEN1KMT2ATSHRGAANPC1
SCHEMBL30731020 0.81 SMN1; SMN2 (0.41) NPC1HTTSMN1; SMN2CYP11B2MAPT
SCHEMBL22553793 0.81 SMN1; SMN2 (0.41) NPC1HTTSMN1; SMN2CYP11B2MAPT
SCHEMBL22553771 0.78 PIP4K2A (0.40) GAANPC1PIP4K2APIP4K2BCYP11B2
SCHEMBL30730847 0.78 PIP4K2A (0.40) GAANPC1PIP4K2APIP4K2BCYP11B2
SCHEMBL22553750 0.77 CYP11B2 (0.39) GAANPC1HTTSMN1; SMN2PIP4K2A
SCHEMBL30730827 0.76 CYP11B2 (0.40) GAANPC1PIP4K2ACYP11B2CD38
SCHEMBL22553742 0.76 CYP11B2 (0.40) GAANPC1PIP4K2ACYP11B2CD38
SCHEMBL22571019 0.74 CYP11B2 (0.39) NPC1PIP4K2ACYP11B2CD38CCNC
SCHEMBL22553727 0.74 ALDH1A1 (0.48) GAANPC1AKR1C3CYP11B2CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112088157-A Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors 拉文纳制药公司 2020-12-15 CN claimed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP claimed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US claimed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 CN disclosed
CN-112088157-A Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors 拉文纳制药公司 2020-12-15 CN disclosed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1A, PIP5K1B, PIP5K1C MEN1 4310/4885KMT2A 1906/4885TSHR 2490/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C MEN1 4310/4885KMT2A 1906/4885TSHR 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.